Table 1.
Distribution and characteristics of the 102MRSA isolates collected at the Istanbul Medical Faculty Hospital between September 2007 and March 2012.
| CC (number of isolates) | MLST assignment (Alere)* | Clone assignment (Alere)* | Number of isolates | % of isolates | agr type | SCCmec type | PVL | Antibiotic resistance ≥90% ** |
|
|---|---|---|---|---|---|---|---|---|---|
| CC8 (60) | CC8 | ST8-MRSA-IV, USA300 | 2 | 2.0 | 1 | IV | + | Kan, Ery, Lvx | |
| CC8/ST239 | ST239-MRSA-III, Vienna/Hungarian/Brazilian Clone | 55 | 53.9 | 1 | III | - | Kan, Tob, Gen, Tet, Rif, Lvx | ||
| CC8/ST72 | ST72-MRSA-IV, USA700 | 3 | 2.9 | 1 | IV | - | Tet, Fus | ||
| CC22 (16) | CC22 | ST22-MRSA-IV [PVL+], "Regensburg EMRSA" | 2 | 2.0 | 1 | IV | + | Kan, Tob, Ery, Lvx | |
| CC22 | ST22-MRSA-IV, "Dublin EMRSA" | 1 | 1.0 | 1 | IV | - | |||
| CC22 | ST22-MRSA-IV, Barnim/UK-EMRSA-15 | 10 | 9.8 | 1 | IV | - | |||
| CC22 | ST22-MRSA-V | 2 | 2.0 | 1 | V | - | |||
| CC22 | None | 1 | 1.0 | 1 | Composite*** | - | Ery, Fus | ||
| CC97 (9) | CC97 | CC97-MRSA-IV, WA MRSA-54/63 | 6 | 5.9 | 1 | IV | - | ||
| CC97 | None | 3 | 2.9 | 1 | Composite*** | - | |||
| CC5 (8) | CC5 | CC5-MRSA-IV, Pediatric clone [sed/j/r-negat. subclone] | 3 | 2.9 | 2 | IV | - | Ery, Lin, Lvx | |
| CC5 | CC5-MRSA-Ivar., WA MRSA-18/21/48 | 3 | 2.9 | 2 | Ivar | - | Kan, Tob | ||
| CC5 | CC5-MRSA-V [sed/j/r-posit. subclone], WA MRSA-11/34/35/87 | 2 | 2.0 | 2 | V | - | |||
| CC1 (6) | CC1 | CC1-MRSA-IV, WA MRSA-1/57 | 5 | 4.9 | 3 | IV | - | ||
| CC1 | CC1-MRSA-V | 1 | 1.0 | 3 | V | - | Ery, Lvx | ||
| CC80 (3) | CC80 | CC80-MRSA-IV [PVL+], European CA-MRSA Clone | 3 | 2.9 | 3 | IV | + | Kan, Fus | |
| Total | 102 | 100.0 |
*MLST and clone assignments (Alere) correspond to the comparison of the hybridization profiles on the microarray to previously typed MLST reference strains (3, 25). "None" denotes characterized isolates that do not correspond to any clone whose microarray profile is already known.
** Kan: kanamycin; Tob: tobramycin; Gen: gentamicin; Chl: chloramphenicol; Tet: tetracycline; Ery: erythromycin; Lin: lincomycin; Pri: pristinamycin; Rif: rifampicin; Sxt: trimethoprim-sulfamethoxazole; Lvx: levofloxacin; Fos: fosfomycin; Fus: fusidic acid.
*** Composite types correspond to unusual combinations of SCCmec elements.